Keyword Search
Keyword=Therapy

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2002 Program page
  300828  By:  Feng  Tang 8:50 AM 08/12/2002
Designing Dose Individualization for Transplant Anti-Cancer Therapy Based on Bayesian Population Pharmacokinetic Model

  300377  By:  Stephanie R. Land 9:35 AM 08/12/2002
Assessment and Analysis of QOL Outcomes in Cancer Clinical Trials: The NSABP Experience

  301463  By:  Dirk F. Moore 2:50 PM 08/12/2002
Predicting the Future Profile of Prostate-specific Antigen Levels Following Radiation Therapy for Prostate Cancer.

  301651  By:  Yolanda  Barrón 9:05 AM 08/14/2002
Marginal Structural Models to Estimate the Causal Effect of Switching Highly Active Antiretroviral Therapy on the Survival of HIV-Positive Women.

  301763  By:  Charlie H. Goldsmith 9:35 AM 08/14/2002
Efficacy Designs when a Placebo Group is Unethical

JSM 2002

For information, contact meetings@amstat.org or phone (703) 684-1221.

If you have questions about the Continuing Education program, please contact the Education Department.

Revised March 2002